Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8444550 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
The addition of cetuximab to chemotherapy improved survival in the first-line treatment of recurrent/metastatic SCCHN and KRAS wild-type mCRC regardless of tumour EGFR expression level, indicating that in contrast to findings in NSCLC, EGFR expression level is not a clinically useful predictive biomarker in these settings.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lisa Licitra, Stephan Störkel, Keith M. Kerr, Eric Van Cutsem, Robert Pirker, Fred R. Hirsch, Jan B. Vermorken, Anja von Heydebreck, Regina Esser, Ilhan Celik, Fortunato Ciardiello,